Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
All three major US stock indexes were up in late-morning trading Tuesday, as oil prices slid despite
Pfizer Inc. (NYSE:PFE) reported first-quarter results that came in ahead of Wall Street forecasts, supported by strong momentum in its recently launched and acquired product portfolio.
Pfizer's (PFE) first-quarter results surpassed analysts' estimates as robust demand across its key b
Early trading behaves as if cooler heads will prevail in the Strait of Hormuz -- and earnings results still matter.
BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m
The Nasdaq Composite (^IXIC) opened higher Tuesday, with the tech-heavy benchmark riding a familiar trio of tailwinds: a fresh wave of strong earnings, a sharp pullback in crude oil, and a pause in Middle East escalation. Risk appetite is back, and the Nasdaq Composite (^IXIC) is riding the bullish wave. Google parent company Alphabet (Nasdaq: GOOGL), ... Alphabet, Intel, Micron Lead Nasdaq Higher as Oil Drops on Paused Mideast Tensions
The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The S&P 500 (^GSPC) heads into Tuesday with momentum after a powerful rebound last month in which the broader markets advanced 9%. A pullback in crude oil and first-quarter earnings beats are driving today’s gains as the markets embrace a reprieve in the Mideast escalation. The S&P 500 (^GSPC) is capturing those tailwinds for gains ... S&P 500 Rises on Big Tech Bump, Corporate Profits and Oil Price Relief
Pfizer stock edged higher early Tuesday on stronger-than-expected first-quarter sales and earnings. The company kept its outlook.
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Revenue reached $14.45 billion, up 5% year-over-year, as oncology and other recently launched products offset steep declines in COVID products
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q1 CY2026, with sales up 5.4% year on year to $14.45 billion. On the other hand, the company’s full-year revenue guidance of $61 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 3.9% above analysts’ consensus estimates.
Pfizer CEO Albert Bourla and Accenture CEO Julie Sweet discuss how they’re using AI to transform their work. Watch the full episode of The 1 on 1 with CNN at CNN.com/the1on1.
Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Pfizer Inc. (NYSE:PFE) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong performance from its recently launched and acquired products portfolio.
The company said it would exit operations at some manufacturing plants in Germany and Singapore, and cut 1,860 positions in total.
Pfizer shares rose slightly in premarket trading after the company delivered a first-quarter earnings beat and reaffirmed its full-year outlook. The drugmaker posted adjusted earnings of 75 cents a share, ahead of the 72 cents Wall Street had forecast. Pfizer reaffirmed its full-year guidance, which it initially provided in December.
Earnings season revs up the next few days as investors will hear from big companies including Advanced Micro Devices, CoreWeave, Pfizer and McDonald's. Data on the U.S. jobs market will also be watched closely, culminating in April nonfarm payroll numbers Friday.
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.
The markets got an unwelcome reminder today that the war in Iran isn’t over, clouding a picture that’s recently been dominated by sunny earnings reports. On Monday, the Dow Jones Industrial Average lost 557 points, or 1.1%, while the S&P 500 declined 0.4% and the Nasdaq Composite slipped 0.2%; the latter two had closed out last week at fresh highs. The war in the Middle East, which Wall Street had all but ignored in recent weeks, flared back into view on Monday.
Asking for a Trend Host Josh Lipton previews several of the biggest stories to come tomorrow, Tuesday, May 5, including earnings results from Advanced Micro Devices (AMD), Pfizer (PFE), and Anheuser-Busch Inbev (BUD); fresh labor data in the form of the latest Job Openings and Labor Turnover Survey (JOLTS) report; and commentary from Federal Reserve Vice Chair for Supervision Michelle Bowman and Governor Michael Barr.
Pfizer Inc. will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per share. That’s down from 92 cents per share in the year-ago period. Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around the company, some investors are eyeing potential gains from its dividends. Currently,
Pfizer Inc. (NYSE:PFE) was among the stocks on Jim Cramer’s radar on Mad Money as he discussed the upcoming earnings. Cramer noted that the stock was cheap with a good yield, as he remarked: Hey, can Pfizer break out of its multi-year rut? Now, a lot depends on the presentation because I haven’t seen any […]
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs. Moderna leaned on cost cuts and international expansion to soften a steep COVID revenue cliff. Two very different pharma stories, both shaped by life ... Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
